Three conventional-drug combination (ifosfamide, carboplatin, etoposide - ICE regimen) in advanced non-small cell lung cancer (NSCLC)

A. M. Cuomo, F. S. Robustelli Della Cuna, P. Baiardi, R. Torazzo, P. Preti, G. Robustelli Della Cuna

Research output: Contribution to journalArticle

Abstract

Fifty consecutive patients with stage IIIB-IV non-small cell lung cancer (NSCLC) received the ICE regimen at intermediate doses (ifosfamide 1 g/m2, carboplatin 120 mg/m2, etoposide 80 mg/m2, day 1 to 3, q.4 weeks, for a maximum of 6 cycles). Overall 2 complete response (CR) and 10 partial response (PR) (overall response, OR: 24%, 95% C.I. 14-37%) were observed. An additional 7 patients had stable disease (SD) lasting more than 6 months, therefore a clinical benefit (CR+PR+SD >6 mos) was achieved in 19 patients (38%). Median time-to-progression (TTP) was 7 months and median overall survival (OS) was 11 months; 1- and 2-year survival rates were 36% and 10%. The ICE regimen was well tolerated and devoid of any cardiac, hepatic or neurologic toxicity. Moderate nausea and vomiting were easily manageable, grade 2 alopecia was universal, while hematological toxicity was mild (grade 2 leuko- and thrombocytopenia). Due to its efficacy and safety profile, this 3-drug regimen can be considered for routine community use.

Original languageEnglish
Pages (from-to)434-439
Number of pages6
JournalJournal of Chemotherapy
Volume13
Issue number4
Publication statusPublished - 2001

Keywords

  • Carboplatin
  • Dose-intensity
  • Etoposide
  • ICE regimen
  • Ifosfamide
  • Non-small cell lung cancer
  • Systemic toxicity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Three conventional-drug combination (ifosfamide, carboplatin, etoposide - ICE regimen) in advanced non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

  • Cite this

    Cuomo, A. M., Robustelli Della Cuna, F. S., Baiardi, P., Torazzo, R., Preti, P., & Robustelli Della Cuna, G. (2001). Three conventional-drug combination (ifosfamide, carboplatin, etoposide - ICE regimen) in advanced non-small cell lung cancer (NSCLC). Journal of Chemotherapy, 13(4), 434-439.